
NovaBridge Biosciences (NBP) Stock Forecast & Price Target
NovaBridge Biosciences (NBP) Analyst Ratings
Bulls say
NovaBridge Biosciences is a promising company with a positive outlook due to its diverse pipeline of innovative immunotherapy drugs, including its lead asset givastomig, a potential treatment for gastric cancer and other gastrointestinal malignancies. The company's recent updates on givastomig and VIS-101 demonstrate their potential to become differentiated assets in the anti-VEGF market through their clinical durability and unique mechanism of action. The company's "hub-and-spoke" business model and ongoing development efforts only add to its potential upside and reinforce our confidence in its long-term success.
Bears say
NovaBridge Biosciences is experiencing financial struggles due to a net loss of $37.9M and negative cash flow from operating activities of $32.9M in the first half of 2026. Additionally, their main product, givastomig, may face challenges as it competes with similar anti-VEGF drugs and the company will need to closely monitor updates and efficacy of their drugs in larger trials. Furthermore, research efforts should focus on refining assumptions around market capture and examining the correlation between early gastritis and givastomig's efficacy.
This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.
NovaBridge Biosciences (NBP) Analyst Forecast & Price Prediction
Start investing in NovaBridge Biosciences (NBP)
Order type
Buy in
Order amount
Est. shares
0 shares